Bessemer Group Inc. maintained its position in Omnicell, Inc. (NASDAQ:OMCL) during the second quarter, according to its most recent disclosure with the SEC. The firm owned 45,659 shares of the company’s stock at the end of the second quarter. Bessemer Group Inc.’s holdings in Omnicell were worth $1,968,000 as of its most recent filing with the SEC.

Other institutional investors have also bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in Omnicell during the fourth quarter worth approximately $788,000. AQR Capital Management LLC increased its position in Omnicell by 26.6% in the fourth quarter. AQR Capital Management LLC now owns 24,935 shares of the company’s stock worth $845,000 after buying an additional 5,236 shares in the last quarter. Norges Bank acquired a new position in Omnicell during the fourth quarter worth approximately $10,913,000. UBS Asset Management Americas Inc. increased its position in Omnicell by 9.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 188,158 shares of the company’s stock worth $6,378,000 after buying an additional 15,779 shares in the last quarter. Finally, First National Bank of Omaha acquired a new position in Omnicell during the first quarter worth approximately $865,000. Institutional investors own 96.35% of the company’s stock.

Shares of Omnicell, Inc. (NASDAQ:OMCL) opened at 49.00 on Friday. The company has a 50-day moving average of $45.19 and a 200 day moving average of $41.05. Omnicell, Inc. has a 52 week low of $30.35 and a 52 week high of $51.98. The firm’s market capitalization is $1.84 billion.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. The company had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.08 million. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.38 earnings per share. Equities research analysts anticipate that Omnicell, Inc. will post $1.31 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Omnicell, Inc. (OMCL) Stake Maintained by Bessemer Group Inc.” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.watchlistnews.com/omnicell-inc-omcl-stake-maintained-by-bessemer-group-inc/1472448.html.

OMCL has been the subject of a number of recent research reports. Piper Jaffray Companies downgraded shares of Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 price objective for the company. in a research note on Friday, April 21st. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $53.00 price objective (up from $43.00) on shares of Omnicell in a research note on Tuesday, April 25th. CIBC increased their price objective on shares of Omnicell from $43.00 to $53.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 26th. TheStreet downgraded shares of Omnicell from a “b-” rating to a “c+” rating in a research note on Thursday, May 4th. Finally, Zacks Investment Research downgraded shares of Omnicell from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Omnicell currently has a consensus rating of “Buy” and an average price target of $49.00.

In other Omnicell news, EVP Dan S. Johnston sold 16,400 shares of the company’s stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $40.67, for a total value of $666,988.00. Following the completion of the sale, the executive vice president now directly owns 61,696 shares of the company’s stock, valued at approximately $2,509,176.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Peter J. Kuipers sold 18,054 shares of the company’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $50.31, for a total transaction of $908,296.74. Following the completion of the sale, the vice president now directly owns 44,236 shares of the company’s stock, valued at $2,225,513.16. The disclosure for this sale can be found here. Over the last three months, insiders have sold 199,823 shares of company stock valued at $9,301,391. 3.77% of the stock is currently owned by insiders.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.